Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company") informs that during the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022, April 8-13 2022, Company will present the latest data of its oncology projects: RVU120 (SEL120), a program developing a selective CDK8/19 kinase inhibitor as an effective therapy for the treatment of hematologic malignancies and solid tumors, as well as a project developing MTA - cooperative inhibitors of PRMT5 - as a synthetically lethal therapy for the treatment of tumors with MTAP gene deletion.

Abstract/Poster Details:

**Title:** RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells *in vitro* and *in vivo*

**Abstract Number:** 2647

RVU120 is a specific, low nM, selective inhibitor of CDK8/CDK19, currently being tested in a first-in-human Phase Ib clinical trial in patients with metastatic or advanced solid tumors progressing from previous lines of therapy (ClinicalTrials.gov: NCT05052255). Studies on a panel of cell lines representing various subtypes of breast cancer revealed that TNBC cells were highly sensitive to RVU120. Molecular profiling of responder cells indicated high enrichment for mesenchymal stem cells-like subtype. Single agent efficacy of RVU120 has been confirmed in subcutaneous TNBC xenograft models *in vivo* at well tolerated doses. Overall, these studies provide rationale for further development of RVU120 in TNBC patients.

**Session Title:** Novel Targets and Pathways

**Session Date and Time:** Tuesday Apr 12, 2022 9:00 AM - 12:30 PM

**Location:** Poster Section 24
**Title:** Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers  
**Abstract Number:** 1117

Targeting PRMT5 in MTAP-deleted tumors in a synthetic lethal approach represents a promising antitumor strategy across many tumor types. Ryvu has identified a series of MTA-cooperative PRMT5 inhibitors with good drug-like physicochemical properties and block methyltransferase activity with nanomolar IC50 values. Ryvu compounds selectively inhibit the growth of MTAP deleted cancer cells in prolonged 3D culture, which strongly correlates with inhibition of PRMT5-dependent protein symmetric demethylation (SDMA) in those cells. Overall, these studies provide the rationale for the further optimization of chemical series towards a clinical candidate.

**Session Title:** Drug Targets  
**Session Date and Time:** Monday Apr 11, 2022 1:30 PM - 5:00 PM  
**Location:** Poster Section 23

---

**Title:** Trials in Progress – RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors  
**Abstract Number:** 8023

SOL-021 is a Phase I/II clinical trial of RVU120 in patients with metastatic or advanced solid tumors, who have exhausted available treatments, currently ongoing in Poland and Spain (NCT05052255). The study is designed in 2 parts: Part 1 follows a 3+3 dose escalation design, and the primary objectives are to characterize the safety and tolerability of RVU120 as a single agent in patients with different tumors types and determine the RP2D. Part 2 will primarily explore the anti-tumor activity of RVU120 as a single agent in different patient populations. As of a data cutoff of 11 Feb 2022, 5 patients have been enrolled in Part 1 of the study and no DLTs have been observed.

This Trials in Progress abstract is published in cooperation with the Early Clinical Trials Centre and Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland; Early Drug Development Unit (UITM) Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; Dep. of Internal Medicine III, Univ. Clinic, Bonn, Germany and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

**Session Title:** Phase II Trials in Progress  
**Session Date and Time:** Monday Apr 11, 2022 9:00 PM - 12:30 PM  
**Location:** Poster Section 34
Additional information is available on the AACR conference website [http://www.aacr.org](http://www.aacr.org).

The information was considered significant because the research results of projects in the Company’s pipeline are of key importance for its valuation, and the AACR conference is considered one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies and industry investors.

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board